Rhodri Harfoot
Overview
Explore the profile of Rhodri Harfoot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
122
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Basak I, Harfoot R, Palmer J, Kumar A, Quinones-Mateu M, Schweitzer L, et al.
Biomolecules
. 2023 Nov;
13(11).
PMID: 38002279
Besides respiratory illness, SARS-CoV-2, the causative agent of COVID-19, leads to neurological symptoms. The molecular mechanisms leading to neuropathology after SARS-CoV-2 infection are sparsely explored. SARS-CoV-2 enters human cells via...
2.
Saha T, Sinha S, Harfoot R, Quinones-Mateu M, Das S
Pharmaceutics
. 2023 Sep;
15(9).
PMID: 37765198
There is a continuous effort to develop efficient treatments for coronavirus disease 2019 (COVID-19) and other viral respiratory diseases. Among the different strategies, inhaled treatment is considered one of the...
3.
Inhalable dry powder containing remdesivir and disulfiram: Preparation and in vitro characterization
Saha T, Sinha S, Harfoot R, Quinones-Mateu M, Das S
Int J Pharm
. 2023 Sep;
645:123411.
PMID: 37703955
The respiratory tract, as the first and most afflicted target of many viruses such as SARS-CoV-2, seems to be the logical choice for delivering antiviral agents against this and other...
4.
Montgomerie I, Bird T, Palmer O, Mason N, Pankhurst T, Lawley B, et al.
iScience
. 2023 Feb;
26(4):106256.
PMID: 36845030
Emerging SARS-CoV-2 variants pose a threat to human health worldwide. SARS-CoV-2 receptor binding domain (RBD)-based vaccines are suitable candidates for booster vaccines, eliciting a focused antibody response enriched for virus...
5.
Saha T, Sinha S, Harfoot R, Quinones-Mateu M, Das S
Pharmaceutics
. 2022 Jul;
14(7).
PMID: 35890327
SARS-CoV-2, the causative agent of COVID-19, predominantly affects the respiratory tract. As a consequence, it seems intuitive to develop antiviral agents capable of targeting the virus right on its main...
6.
Harfoot R, Lawley B, Hernandez L, Kuang J, Grant J, Treece J, et al.
Viruses
. 2022 Feb;
14(2).
PMID: 35215963
SARS-CoV-2, the virus responsible for the COVID-19 pandemic, has wreaked havoc across the globe for the last two years. More than 300 million cases and over 5 million deaths later,...
7.
Stanton J, OBrien R, Hall R, Chernyavtseva A, Ha H, Jelley L, et al.
Front Public Health
. 2022 Feb;
9:808751.
PMID: 35141190
The rapid global rise of COVID-19 from late 2019 caught major manufacturers of RT-qPCR reagents by surprise and threw into sharp focus the heavy reliance of molecular diagnostic providers on...
8.
Harfoot R, Yung D, Anderson W, Wild C, Coetzee N, Hernandez L, et al.
Pathogens
. 2022 Jan;
11(1).
PMID: 35056031
The arrival of SARS-CoV-2 to Aotearoa/New Zealand in February 2020 triggered a massive response at multiple levels. Procurement and sustainability of medical supplies to hospitals and clinics during the then...
9.
Lawley B, Grant J, Harfoot R, Treece J, Day R, Hernandez L, et al.
Viruses
. 2021 Nov;
13(11).
PMID: 34835031
It has been 20 months since we first heard of SARS-CoV-2, the novel coronavirus detected in the Hubei province, China, in December 2019, responsible for the ongoing COVID-19 pandemic. Since...
10.
Su W, Harfoot R, Su Y, DeBeauchamp J, Joseph U, Jayakumar J, et al.
Nat Microbiol
. 2021 Oct;
6(11):1455-1465.
PMID: 34702977
Understanding the evolutionary adaptations that enable avian influenza viruses to transmit in mammalian hosts could allow better detection of zoonotic viruses with pandemic potential. We applied ancestral sequence reconstruction to...